Top

Supportive Care in Cancer

Published in:

01-12-2019 | Pleural Mesothelioma | Original Article

A survey of patient and caregiver experience with malignant pleural mesothelioma

Authors: Anne Warby, Haryana M. Dhillon, Steven Kao, Janette L. Vardy

Published in: Supportive Care in Cancer | Issue 12/2019

Abstract

Background

Malignant pleural mesothelioma (MPM) is a rare cancer with poor prognosis. As there is little information on the lived experience of MPM, our aim was to document the experience of MPM patients and their caregivers.

Methods

Surveys for MPM patients and caregivers were developed from previous interviews with patients, caregivers, and health professionals, about treatments and decision-making. Participants were recruited from two hospitals, government compensation body, and support groups.

Results

Survey responses were received from 78 MPM patients and 106 caregivers from January to September 2014. Patients: 85% male, median age 69 years, median time since diagnosis 15 months. Caregivers: median age 68, 91% female, 90% spouse of MPM patient, 95% bereaved.

Most participants felt informed about treatment options but only 69% thought all treatment options were discussed. Chemotherapy was discussed most frequently (92–95%); ~80% had sufficient information for decision-making. Decision regarding chemotherapy was made by patient considering doctor’s opinion (24%), doctor and patient equally (18%), and doctor (17%). Participants ‘agreed’/‘strongly agreed’ that they made the right decision about chemotherapy (patients 81%, caregivers 60%), but 5% and 16%, respectively, regretted the decision.

Most participants received ‘sufficient’ support (71%). A quarter reported seeing cancer nurse specialists. Palliative care referral: 31% patients, 85% caregivers. Caregivers would have liked to talk to someone by themselves (41%), more time with doctors (30%), psychological support (29%), and clearer information (31%). Bereaved caregivers requested grief counselling (39%) and post-death consultation with specialists (23–25%).

Conclusions

Satisfaction with treatment was high, but participants identified need for improved communication and quality information, discussion about all treatments, end-of-life assistance, and caregiver support after the patient’s death.

Available only for authorised users

Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366(9483):397–408. https://doi.org/10.1016/S0140-6736(05)67025-0 CrossRefPubMed

Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N (2010) Malignant mesothelioma. Intern Med J 40(11):742–750. https://doi.org/10.1111/j.1445-5994.2010.02223.x CrossRefPubMed

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644. https://doi.org/10.1200/JCO.2003.11.136 CrossRefPubMed

van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research, Treatment of Cancer Lung Cancer Group, National Cancer Institute of Canada (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):6881–6889. https://doi.org/10.1200/JCO.20005.14.589 CrossRefPubMed

Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS (2006) Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based C (2006) The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1(6):591–601CrossRef

Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 22(15):3172–3180. https://doi.org/10.1200/JCO.2004.09.147 CrossRefPubMed

Gralla RJ, Hollen PJ, Liepa AM et al (2003) Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using the LCSS-Meso instrument. Proc Am Soc Clin Oncol Meet 22:Abstract 2496

Clayson H, Seymour J, Noble B (2005) Mesothelioma from the patient’s perspective. Hematol Oncol Clin North Am 19(6):1175–1190, viii. https://doi.org/10.1016/j.hoc.2005.09.003 CrossRefPubMed

Moore S, Darlison L, Tod AM (2010) Living with mesothelioma. A literature review. Eur J Cancer Care (Engl) 19(4):458–468. https://doi.org/10.1111/j.1365-2354.2009.01162.x CrossRef

10.

Arber A, Spencer L (2013) It’s all bad news’: the first 3 months following a diagnosis of malignant pleural mesothelioma. Psychooncology 22(7):1528–1533. https://doi.org/10.1002/pon.3162 CrossRefPubMed

11.

Lee SF, O'Connor MM, Chapman Y, Hamilton V, Francis K (2009) A very public death: dying of mesothelioma and asbestos-related lung cancer (M/ARLC) in the Latrobe Valley, Victoria, Australia. Rural Remote Health 9(3):1183PubMed

12.

Dhillon H, Warby A, Kao SC, Vardy J (2013) Chemotherapy for malignant mesothelioma: patient, caregiver and health professionals’ perceptions of treatment and what influences access. In: IALSC World Conference on Lung Cancer. J Thorac Oncol, Sydney, p S1240

13.

Degner LF, Sloan JA (1992) Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol 45(9):941–950CrossRef

14.

Brehaut JC, O'Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, Feldman-Stewart D (2003) Validation of a Decision Regret Scale. Med Decis Mak 23(4):281–292. https://doi.org/10.1177/0272989X03256005 CrossRef

15.

Sheehan J, Sherman KA, Lam T, Boyages J (2007) Association of information satisfaction, psychological distress and monitoring coping style with post-decision regret following breast reconstruction. Psychooncology 16(4):342–351. https://doi.org/10.1002/pon.1067 CrossRefPubMed

16.

Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381. https://doi.org/10.1016/j.jbi.2008.08.010 CrossRef

17.

Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N (2014) Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 111(9):1860–1869. https://doi.org/10.1038/bjc.2014.478 CrossRefPubMedPubMedCentral

18.

Kao SC, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N (2013) Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Intern Med J 43(4):402–410. https://doi.org/10.1111/j.1445-5994.2012.02925.x CrossRefPubMed

19.

Australian Bureau of Statistics (ABS): Australian Statistical Geography Standard (ASGS) (2011). Statistics ABo. edn., Canberra: Australian Capital Territory

20.

Kao SC, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W (2015) Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care. Asia Pac J Clin Oncol 11(1):85–92. https://doi.org/10.1111/ajco.12306 CrossRefPubMed

21.

Becerra Perez MM, Menear M, Brehaut JC, Legare F (2016) Extent and predictors of decision regret about health care decisions: a systematic review. Med Decis Mak 36(6):777–790. https://doi.org/10.1177/0272989X16636113 CrossRef

22.

Hollen PJ, Gralla R, Coyne B, Hall R, Genzler R, Cheng H, Weiss G, Gildersleeve J, Hinton I, Crawford J, Rosen L, Lesser M Do patients treated with chemotherapy for advanced NSCLC regret having received treatment? A prospective evaluation in 164 patients. In: IASLC World Conference on Lung Cancer, Yokohama, 2017. vol 11. J Thorac Oncol, p S1834

23.

Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742. https://doi.org/10.1056/NEJMoa1000678 CrossRefPubMed

24.

Dionne-Odom JN, Azuero A, Lyons KD, Hull JG, Tosteson T, Li Z, Li Z, Frost J, Dragnev KH, Akyar I, Hegel MT, Bakitas MA (2015) Benefits of early versus delayed palliative care to informal family caregivers of patients with advanced cancer: outcomes from the ENABLE III randomized controlled trial. J Clin Oncol 33(13):1446–1452. https://doi.org/10.1200/JCO.2014.58.7824 CrossRefPubMedPubMedCentral

25.

Brims FG, Gunatilake S, Lawrie I (2017) RESPECT-MESO: an international randomised controlled trial to assess early specialist palliative care in malignant pleural mesothelioma. In: IASLC World Conference on Lung Cancer, Yokohama, Japan. vol 11. J Thorac Oncol, pp S1747–S1748

26.

Palos GR, Mendoza TR, Liao KP, Anderson KO, Garcia-Gonzalez A, Hahn K, Nazario A, Ramondetta LM, Valero V, Lynch GR, Jibaja-Weiss ML, Cleeland CS (2011) Caregiver symptom burden: the risk of caring for an underserved patient with advanced cancer. Cancer 117(5):1070–1079. https://doi.org/10.1002/cncr.25695 CrossRefPubMed

27.

Stenberg U, Ruland CM, Miaskowski C (2010) Review of the literature on the effects of caring for a patient with cancer. Psychooncology 19(10):1013–1025. https://doi.org/10.1002/pon.1670 CrossRefPubMed

28.

Trevino KM, Prigerson HG, Maciejewski PK (2018) Advanced cancer caregiving as a risk for major depressive episodes and generalized anxiety disorder. Psychooncology 27(1):243–249. https://doi.org/10.1002/pon.4441 CrossRefPubMed

29.

Trevino KM, Maciejewski PK, Epstein AS, Prigerson HG (2015) The lasting impact of the therapeutic alliance: patient-oncologist alliance as a predictor of caregiver bereavement adjustment. Cancer 121(19):3534–3542. https://doi.org/10.1002/cncr.29505 CrossRefPubMedPubMedCentral

30.

Prigerson HG, Bierhals AJ, Kasl SV, Reynolds CF 3rd, Shear MK, Newsom JT, Jacobs S (1996) Complicated grief as a disorder distinct from bereavement-related depression and anxiety: a replication study. Am J Psychiatry 153(11):1484–1486. https://doi.org/10.1176/ajp.153.11.1484 CrossRefPubMed

31.

Hudson P, Remedios C, Zordan R, Thomas K, Clifton D, Crewdson M, Hall C, Trauer T, Bolleter A, Clarke DM, Bauld C (2012) Guidelines for the psychosocial and bereavement support of family caregivers of palliative care patients. J Palliat Med 15(6):696–702. https://doi.org/10.1089/jpm.2011.0466 CrossRefPubMedPubMedCentral

Title: A survey of patient and caregiver experience with malignant pleural mesothelioma
Authors: Anne Warby
Haryana M. Dhillon
Steven Kao
Janette L. Vardy
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keywords: Pleural Mesothelioma
Pleural Mesothelioma
Cytostatic Therapy
Published in: Supportive Care in Cancer / Issue 12/2019
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-04760-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2019

Social disparities and symptom burden in populations with advanced cancer: specialist palliative care providers’ perspectives

Promoting assessment and management of function through navigation: opportunities to bridge oncology and rehabilitation systems of care

The role of parenteral nutrition in patients with malignant bowel obstruction

Acceptability and feasibility of a therapeutic board game for children and adolescents with cancer: the Italian version of Shop Talk

Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy

Validation of the Chinese version of the Head and Neck Patient Symptom Checklist for measuring nutrition impact symptoms during radiotherapy in patients with head and neck cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer